National Heart, Lung and Blood Institute (NHLBI)s

National Heart, Lung and Blood Institute (NHLBI)

163 Protocols (86 Active Accrual of new subjects, 77 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 20-H-0141:
Longterm Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

* 20-H-0137:
Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects with Stable Sickle Cell Disease

* 20-H-0100:
Expanded Access to Convalescent Plasma for the Treatment of Patients COVID-19

* 20-H-0099:
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

* 20-H-0080:
Red Cell Half Life Determination in Patients with and without Sickle Cell Disease

* 20-H-0068:
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

* 20-H-0049:
NHLBI DIR Cardiovascular Branch PK Papyrus Covered Stent Ethics Oversight of Humanitarian Use Device for Treatment of Acute Perforations of Native Coronary Arteries and Coronary Bypass Grafts in Vessels 2.5 to 5.0 mm in Diameter

* 20-H-0044:
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

* 20-H-0033:
Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

* 20-H-0029:
An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

* 20-H-0021:
Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag

* 20-H-0016:
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

* 19-H-0139:
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance

* 19-H-0120:
Pilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women

* 19-H-0118:
Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

* 19-H-0111:
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

* 19-H-0100:
Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy

* 19-H-0097:
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects with Stable Sickle Cell Disease

* 19-H-0088:
NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

* 19-H-0057:
Multiple Patient Program for Lamprene (clofazimine) for the Treatment of Non-Tuberculous Mycobacterial (NTM) Infections

* 19-H-0001:
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy

* 18-H-0146:
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease

* 18-H-0145:
Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated with Bruton's -Tyrosine Kinase Inhibitor (BTK-I)

* 18-H-0118:
Technical and Translational Development of Cardiovascular MRI (CMR)

* 18-H-0108:
Vascular Disease Discovery Protocol

* 18-H-0090:
Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphomide for GVHD Prophylaxis

* 18-H-0019:
Effect of Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

* 18-H-0012:
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma

* 18-H-0011:
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

* 18-H-0004:
Low Dose Danazol for the Treatment of Telomere Related Diseases

* 18-H-0003:
Discovery of Sirolimus Sensitive Biomarkers in Blood

* 17-H-0162:
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments: A Multi-Level, Community-Based Physical Activity Intervention

* 17-H-0142:
Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

* 17-H-0121:
Eltrombopag for Patients with Fanconi Anemia

* 17-H-0118:
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

* 17-H-0095:
Heart Catheterization using MRI Fluoroscopy and Passive Guidewires

* 17-H-0091:
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

* 17-H-0069:
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

* 17-H-0019:
A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

* 16-H-0144:
Impact of Elastin Mediated Vascular Stiffness on End Organs

* 16-H-0089:
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction

* 16-H-0074:
Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank

* 15-H-0190:
Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

* 15-H-0024:
Genes Involved in Lipid Disorders

* 15-H-0017:
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

* 14-H-0188:
Prospective Evaluation of Next Generation CT Reconstruction

* 14-H-0155:
A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobinA BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease

* 14-H-0127:
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders

* 14-H-0077:
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure

* 13-H-0194:
Inflammatory Characterization of Known or Possible Cardiovascular Diseases

* 13-H-0183:
Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention

* 13-H-0116:
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

* 13-H-0065:
Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative

* 13-H-0059:
Longitudinal Observational Study of Severe Asthma

* 13-H-0051:
13-H-0051 Bronchodilator Effects of Nebulized versus Inhaled Albuterol in subjects with Lymphangioleiomyomatosis

* 12-H-0150:
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

* 12-H-0141:
Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography

* 12-H-0064:
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

* 10-H-0168:
Submission of Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant Data to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP)

* 10-H-0154:
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells

* 10-H-0126:
Cardiovascular Disease Discovery Protocol

* 09-H-0172:
Natural History of Bronchiectasis

* 08-H-0186:
Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity with Bortezomib

* 08-H-0156:
Screening of Subjects to Determine Eligibility to Safely Participate in Blood Disorders Studies

* 08-H-0105:
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lmphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

* 07-H-0142:
Research Respiratory Tract Procedures

* 07-H-0113:
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers

* 07-H-0030:
Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome

* 07-H-0005:
Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease

* 05-H-0130:
Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants

* 04-H-0161:
Studies of the Natural History of Sickle Cell Disease

* 04-H-0012:
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members

* 03-H-0280:
Disease Pathogenesis and Natural History of Lipid Disorders

* 03-H-0170:
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia

* 03-H-0105:
The Determination of Genetic Basis Of Immunodeficiency

* 03-H-0015:
Human Specimen Collection to Support Basic and Clinical Research

* 02-H-0160:
Peripheral Blood Stem Cell Collection from Adult Volunteers

* 01-H-0122:
Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy

* 00-H-0051:
Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis

* 99-H-0076:
Asthma Sample Collection Protocol

* 97-H-0061:
Evaluation and Treatment of Pulmonary Patients not Participating in Research (Training Protocol)

* 97-H-0041:
Screening Protocol for Subjects Being Evaluated for National Heart, Lung and Blood Institute (NHLBI) Protocols

* 96-H-0100:
Role of Genetic Factors in the Pathogenesis of Lung Disease

* 96-H-0049:
Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation

* 95-H-0186:
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

* 94-H-0010:
Evaluation, Treatment and Training Protocol for Patients with Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies

Active Follow-up, Protocols NOT Recruiting New Patients 

* 19-H-0034:
Exploratory Study of Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

* 17-H-0146:
Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)

* 17-H-0124:
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor

* 17-H-0056:
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease

* 17-H-0026:
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

* 16-H-0174:
A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

* 16-H-0132:
CADASIL Disease Discovery

* 16-H-0129:
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

* 16-H-0123:
Safety and Efficacy of Saracatinib in Subjects with Lymphangioleiomyomatosis (LAM) (SLAM-2)

* 16-H-0085:
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate

* 16-H-0063:
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)

* 16-H-0019:
High Image Matrix CT Reconstruction

* 15-H-0173:
Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

* 15-H-0172:
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Next 63 Protocols

09/25/2020